Dermata Therapeutics (DRMA) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free DRMA Stock Alerts $0.38 +0.02 (+5.56%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative February 11, 2024 | ca.finance.yahoo.comDermata Therapeutics, Inc. (DRMAW)February 6, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowFebruary 4, 2024 | morningstar.comDermata Therapeutics Inc DRMAFebruary 1, 2024 | finance.yahoo.comDermata to Present at the Emerging Growth Conference on February 7, 2024January 7, 2024 | msn.comDermata stock soars on patent issuance, partnership talksJanuary 5, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?January 5, 2024 | investorplace.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 4, 2024 | marketwatch.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | msn.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | finance.yahoo.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisDecember 21, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | finance.yahoo.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 13, 2023 | thestreet.comDermata Therapeutics Inc.November 16, 2023 | finance.yahoo.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.comDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 ProtocolsNovember 10, 2023 | msn.comDermata Therapeutics GAAP EPS of -$0.54November 9, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne TrialAugust 31, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJune 27, 2023 | finance.yahoo.comDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe AcneJune 13, 2023 | finance.yahoo.comDermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETJune 8, 2023 | finance.yahoo.comJournal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsJune 8, 2023 | finanznachrichten.deDermata Therapeutics: Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsMay 26, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 24, 2023 | finance.yahoo.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 24, 2023 | msn.comDermata Therapeutics announces $1.8M offering priced ATMMay 24, 2023 | finance.yahoo.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 12, 2023 | marketwatch.comDermata Therapeutics Shares Rally Premarket on DMT310 Update >DRMAMay 11, 2023 | seekingalpha.comDermata Therapeutics GAAP EPS of -$2.27May 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | proactiveinvestors.comDermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studiesApril 21, 2023 | finance.yahoo.comDermata (DRMA) Gains on Positive FDA Response for Acne CandidateApril 20, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting PackageApril 20, 2023 | msn.comDermata climbs ~28% after update on acne candidateApril 20, 2023 | finance.yahoo.comDermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting PackageMarch 31, 2023 | benzinga.comDermata Therapeutics Inc (DRMA) has risen 6.40% Wednesday In Premarket TradingMarch 26, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA), Guidance and ForecastMarch 24, 2023 | markets.businessinsider.comWhy Is Allarity Therapeutics (ALLR) Stock Down 23% Today?March 23, 2023 | marketbeat.comTrading was temporarily halted for "DRMA" at 02:03 PM with a stated reason of "LULD pause."March 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 16, 2023 | marketwatch.comDermata Therapeutics Up 24% After Boosting Size of OfferingMarch 16, 2023 | finance.yahoo.comDermata Therapeutics Announces Pricing of $5.0 Million Public OfferingFebruary 28, 2023 | seekingalpha.comDRMA Dermata Therapeutics, Inc.February 21, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial ResultsDecember 30, 2022 | benzinga.comThinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab? Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. DRMA Media Mentions By Week DRMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRMA News Sentiment▼1.890.57▲Average Medical News Sentiment DRMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRMA Articles This Week▼10▲DRMA Articles Average Week Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLRX News Today CNSP News Today CWBR News Today SXTP News Today SNOA News Today GLMD News Today BPTH News Today NTBL News Today CMND News Today ATXI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRMA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.